Sam Collins

Sam Collins

Sam Collins is  InvestorPlace.com’s Chief Technical Analyst. He has more than four decades of experience in Wall Street firms.

In addition to providing fundamental and technical analysis for InvestorPlace.com, he provides FREE daily market commentary each trading day via the Daily Trader’s Alert. The Daily Trader’s Alert contains his Daily Market Outlook PLUS a Trade of the Day.

Sam served as a regular army captain serving in West Germany during the Berlin Wall Crisis before joining Merrill Lynch as a futures broker. Since then, he has been a financial adviser, branch manager, regional manager and certified portfolio manager with national and regional securities firms. While he retired in October 2009, during his career, he received recognition and numerous awards.

Sam used technical analysis as a timing and selection technique with portfolios that he managed. He developed a specific technical analysis technique and timing system called the Collins Bollinger Reversal (CBR) that has received national recognition, and he has appeared on local and national TV as a financial commentator.

As an equity specialist and technician, he uses technical analysis as a selection technique along with fundamental analysis. As a value buyer, his goal is to find companies with outstanding management, unique products and strong financials that have not yet been driven to unreasonable prices. His CBR system helps him to screen vast amounts of data for stocks that meet those standards.

Sam is also a member of the NASD Board of Arbitrators.

Recent Articles

Tech Stocks Fail to Bail Out the Market

Many analysts have been counting on the sector, but it is faring poorly as well.

Why You Should Sell This Week

The chances of moving through overhead resistance are slim.

Is This Market Running Out of Steam?

With tech stocks and financials canceling each other out, the likelihood of a sideways move is increasing.

The Only Stock That Really Matters Today

The indices could rise into the upper range of resistance or be in for a big pullback.

Overbought Biotech Still a Good Buy

Celgene Corp.’s breakout is so strong that it could remain overbought for some time. Get the target.